3347 Stock Overview
Provides contract research organization services in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥32.35 |
| 52 Week High | CN¥58.80 |
| 52 Week Low | CN¥22.10 |
| Beta | 0.85 |
| 11 Month Change | -15.54% |
| 3 Month Change | 13.91% |
| 1 Year Change | -25.20% |
| 33 Year Change | -75.00% |
| 5 Year Change | n/a |
| Change since IPO | -71.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3347 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -5.4% | -7.1% | -0.6% |
| 1Y | -25.2% | -58.3% | 9.6% |
Return vs Industry: 3347 exceeded the Hong Kong Life Sciences industry which returned -57.6% over the past year.
Return vs Market: 3347 underperformed the Hong Kong Market which returned 10.1% over the past year.
Price Volatility
| 3347 volatility | |
|---|---|
| 3347 Average Weekly Movement | 16.1% |
| Life Sciences Industry Average Movement | 12.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 3347's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3347's weekly volatility has increased from 11% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,348 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| 3347 fundamental statistics | |
|---|---|
| Market cap | HK$52.60b |
| Earnings (TTM) | HK$1.03b |
| Revenue (TTM) | HK$7.30b |
55.1x
P/E Ratio7.8x
P/S RatioIs 3347 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3347 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.80b |
| Cost of Revenue | CN¥4.27b |
| Gross Profit | CN¥2.54b |
| Other Expenses | CN¥1.58b |
| Earnings | CN¥958.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.11 |
| Gross Margin | 37.29% |
| Net Profit Margin | 14.10% |
| Debt/Equity Ratio | 15.2% |
How did 3347 perform over the long term?
See historical performance and comparison